SCHEMBL3150776

SCHEMBL3150776

NC(=O)Oc1ccc(I)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
KIF11 P52732 1/20 0.50
CA1 P00915 4/20 0.45
CA2 P00918 4/20 0.45
CA9 Q16790 2/20 0.45
TPMT P51580 1/20 0.41
CA12 O43570 1/20 0.41
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
PARP10 Q53GL7 2/20 0.38
ALDH1A1 P00352 1/20 0.38
PARP15 Q460N3 1/20 0.38
PARP14 Q460N5 1/20 0.38
PARP16 Q8N5Y8 1/20 0.38
PARP11 Q9NR21 1/20 0.38
PARP4 Q9UKK3 1/20 0.38
SLC22A2 O15244 1/20 0.38
SLC22A1 O15245 1/20 0.38
SLC22A3 O75751 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284986 0.87 KMT2A (0.64) KMT2AMEN1KIF11CA1CA2
SCHEMBL7866352 0.80 MEN1 (0.50) KMT2AMEN1CA1CA2CA9
SCHEMBL1850368 0.78 KMT2A (0.54) KMT2AMEN1KIF11PARP10ALDH1A1
SCHEMBL348122 0.78 MEN1 (0.54) KMT2AMEN1KIF11CA2PARP10
SCHEMBL7871721 0.78 TPMT (0.48) CA1CA2CA9TPMTCA12
SCHEMBL473211 0.76 LMNA (0.64) KMT2AMEN1KIF11CA1CA2
SCHEMBL936193 0.76 MEN1 (0.52) KMT2AMEN1KIF11CA1CA2
SCHEMBL22923566 0.76 KMT2A (0.52) KMT2AMEN1KIF11CA1CA2
SCHEMBL731242 0.76 CA1 (0.61) KMT2AMEN1KIF11CA1CA2
SCHEMBL81261 0.76 MEN1 (0.52) KMT2AMEN1KIF11CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101632016-B Optical isomer separating filler DAICEL CHEM 2013-12-25 CN claimed
CN-101632016-A Optical isomer separating filler DAICEL CHEM 2010-01-20 CN claimed
CN-114957248-B Pyrrolo pyrimidine compound and preparation method, pharmaceutical composition and application thereof 南开大学 2023-12-29 CN disclosed
CN-116731045-A KRAS inhibitor, preparation method and application thereof 北京华森英诺生物科技有限公司 2023-09-12 CN disclosed
CN-115515934-A NAMPT modulators 赛特凯恩蒂克公司 2022-12-23 CN disclosed
CN-114957248-A Pyrrolopyrimidine compound, and preparation method, pharmaceutical composition and application thereof 南开大学 2022-08-30 CN disclosed
WO-2022012622-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2022-01-20 WO disclosed
CN-109952300-B 5-or 8-substituted imidazo [1,5-a ] pyridines 百济神州有限公司 2022-01-18 CN disclosed
CN-108025189-B Molecules having pesticidal utility, and intermediates, compositions and methods related thereto 美国陶氏益农公司 2021-07-02 CN disclosed
CN-112877079-A Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element 深圳清荷科技有限公司 2021-06-01 CN disclosed
WO-2019190117-A1 2-CYANOPYRIMIDIN-4-YL CARBAMATE OR UREA DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME 한림제약(주) 2019-10-03 WO disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 US disclosed
US-7141588-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER, INC. (US) 2006-11-28 US disclosed
EP-1478629-B1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN CO LLC (US) 2006-10-11 EP disclosed
US-6919329-B2 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY (US) 2005-07-19 US disclosed
CN-1639135-A N-aryl-2-oxazolidinone-5-amides and derivatives thereof and their use as antibacterial agents UPJOHN CO (US) 2005-07-13 CN disclosed
EP-1478629-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2004-11-24 EP disclosed
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 US disclosed
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-03-04 US disclosed
WO-2003072553-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 KMT2A 1273/4885MEN1 3522/4885KIF11 3930/4885
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 KMT2A 1273/4885MEN1 3522/4885KIF11 3930/4885
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 KMT2A 1273/4885MEN1 3522/4885KIF11 3930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.